Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. develops clinical-stage cancer therapeutics, with news centered on micvotabart pelidotin, or MICVO, an investigational antibody-drug conjugate targeting extradomain-B fibronectin in the tumor extracellular matrix. Company updates focus on MICVO in solid tumors, including recurrent or metastatic head and neck squamous cell carcinoma, and on monotherapy and pembrolizumab combination development.
Recurring developments include clinical and preclinical data presentations, translational research on MICVO’s mechanism of action, quarterly and annual financial results, corporate presentations, leadership changes, business development appointments, and capital actions tied to funding the company’s oncology pipeline.
Pyxis Oncology, a clinical stage company developing next-gen cancer therapies, announced its participation in the BTIG Virtual Biotechnology Conference. The event is scheduled for August 5-6, 2024. Lara S. Sullivan, M.D., President and CEO of Pyxis, along with other management members, will engage in one-on-one meetings during the conference.
This participation highlights Pyxis Oncology's commitment to advancing its pipeline of therapeutics targeting difficult-to-treat cancers. The company's presence at this virtual event provides an opportunity for investors and industry professionals to gain insights into Pyxis's ongoing developments and strategic direction in the oncology field.
Pyxis Oncology, a clinical stage company, announced the grant of restricted stock units and stock options to five new employees under its 2022 Inducement Plan. The total grants include 89,530 shares of common stock and options to purchase 111,913 shares at an exercise price of $3.31 per share. These awards, aligned with Nasdaq Listing Rule 5635(c)(4), serve as an inducement for employment and will vest over four years. The initial 25% of the grants will vest on the first anniversary, with the remaining shares vesting monthly over the subsequent three years.
Pyxis Oncology (Nasdaq: PYXS) has appointed Michael A. Metzger to its Board of Directors, effective June 10, 2024. Metzger brings over 25 years of biopharmaceutical experience and is currently the CEO of Syndax Pharmaceuticals. Pyxis CEO Lara S. Sullivan emphasized Metzger's expertise and leadership in innovation as vital for the company's growth, particularly in advancing their antibody-drug conjugates (ADCs) aimed at treating challenging cancers. Metzger expressed enthusiasm for contributing to Pyxis's mission of improving cancer treatment outcomes.
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on next-generation cancer therapeutics, announced that its President and CEO, Lara S. Sullivan, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:00 AM Eastern Time in New York City. The management team will also hold one-on-one meetings with investors. The event will be webcast live, with a replay available on the company's Investor Relations website.
Pyxis Oncology (Nasdaq: PYXS) announced its Q1 2024 financial results and corporate updates. PYX-201's Phase 1 trial has dosed 42 patients and aims to dose 16 more, with readout expected in fall 2024. PYX-106's Phase 1 trial, targeting NSCLC and other cancers, has dosed 24 patients, with data expected in 2H 2024. The company presented new preclinical data and expanded its leadership team with Stephen Worsley as Chief Business Officer. Q1 2024 financial highlights include revenues of $16.1M, R&D expenses of $13M, and a net loss of $3.3M. Cash runway is expected to last into 2H 2026.
Pyxis Oncology, Inc. (Nasdaq: PYXS) will be presenting at the RBC Capital Markets Global Healthcare Conference where the President and CEO will participate in a fireside chat and host investor meetings. The event will take place on May 14, 2024, at 3:05 PM ET.
Summary not available.
Summary not available.
Summary not available.
Summary not available.